Mersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...
Finanznachrichten35m
Tharimmune Inc.: Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
This new patent complements Tharimmune's existing pipeline, including colonic targeting developed ... Subsequent events and developments may cause Tharimmune's views to change; however, Tharimmune ...
TMCnet6m
Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain ...